REFERENCES
- Tyre11 CJ. Controversies in the management of advanced prostate cancer. Br J Cancer 1999; 79: 146–55.
- Mole PA, McMurdo MET, Paterson CR. Evaluation of peripheral dual energy X-ray absorptiometry: compari-son with single photon absorptiometry of the forearm and dual energy X-ray absorptiometry of the spine or femur. Br J Radiol 1998; 71: 427–32.
- Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, et al. Androgen deprivation therapy for prostatic cancer results in significant loss of bone density. Urology 1999; 54: 607–11.
- Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181–6.
- Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127–32.
- Stoch SA, Parker RA, Chen L, Bubley G, Ko Y-J, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787–91.
- Daniell HW. Osteoporosis after orchidectomy for prostate cancer. J Urol 1997; 157: 439–44.
- Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteiniz-ing hormone-releasing agonists for prostate cancer. BJU Int 2000; 86: 449–52.
- Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occur-rence of osteoporotic fractures. Br Med J 1996; 312: 1254–9.
- Jones G, White C, Nguyen T, Sambrook PN, Kelly PJ, Eisman JA. Prevalent vertebral deformities: relationship to bone mineral density and osteophytosis in elderly men and women. Osteoporosis Int 1996; 6: 233–9.
- Kaisary AV, Tyrell CJ, Peeling WB, Griffiths K. Comparison of LH-RH analogue (Zoladex) with orchi-dectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502–8.
- Schroder FH. The future of endocrine treatment in early prostate cancer: concluding remarks. Eur Urol 1999; 36 Suppl 2: 27–30.
- Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men. J Clin Invest 1997; 100: 1755–9.
- Stege R. Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl 2000; 10: 38–42.
- Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561–6.